OSR Holdings, Inc. Stock Price, News & Analysis

OSR Holdings (NASDAQ: OSRH) reported results from a company-sponsored pilot study (May 9–Sep 12, 2023) of Woori IO's Glucheck noninvasive glucose system, using 140 datasets versus a Beckman Coulter AU5800 reference. Key findings: >90% of measurements across both device models met ≥85% accuracy; repeatability showed 5% CV; correlation coefficients exceeded 0.900; all readings fell in Zones A/B of Clarke and Consensus Error Grids and met ISO 15197:2013 acceptance criteria. Both mouse and stick form factors produced comparable results. The study was exploratory (not MFDS-registered) and underpins ongoing PoC work with Samsung and a planned MFDS-compliant trial in H1 2026.

OSR Holdings (NASDAQ: OSRH) executed a definitive agreement to acquire Woori IO (WORIO), a developer of near-infrared spectroscopy (NIRS)-based noninvasive continuous glucose monitoring (NIGM).

WORIO shareholders will receive newly issued OSR Holdings Co., Ltd. (OSRK) shares valued at KRW15bn (~$10.5M); if OSRH reaches $10 per share within 3 years, OSRK shares may convert into OSRH common stock at a 12.96:1 ratio (≈1.09M new shares). WORIO has a partnership with a major global consumer electronics company and plans clinical trials in Seoul to support regional regulatory pathways.

OSR Holdings (NASDAQ:OSRH) has received a deficiency notice from Nasdaq for failing to maintain the minimum bid price requirement of $1.00 per share. The company has until March 4, 2026 to regain compliance, and its stock will continue trading on the Nasdaq Capital Market.

Despite share price volatility, OSR Holdings emphasizes its ongoing initiatives, including advancement of oral immunotherapies and regenerative medicine programs, development of its Digital Asset Treasury strategy, and due diligence on Woori IO's glucose monitoring technology. The company has identified unusual trading patterns and elevated fails-to-deliver data, suggesting possible manipulative short selling affecting its stock price.

OSR Holdings (NASDAQ: OSRH) will host a Virtual Investor Event on August 6, 2025, at 8:00 a.m. ET to provide comprehensive corporate updates and strategic direction. The event will feature presentations from senior executives including CEO Peter Hwang, CSO Dr. Constance Höfer, and Global IR Tim Smith.

Key agenda items include updates on subsidiary operations, R&D pipeline developments, capital allocation strategy, and the company's blockchain initiatives. Notable focus areas include Vaximm's T-cell immunotherapies, Darnatein's DRT101 DMOAD candidate, and the Woori IO acquisition for noninvasive CGM development.

The virtual event will be accessible via livestream, with registration opening on August 4 through the company's website. A replay will be available afterward on OSR Holdings' Investor Relations website.

OSR Holdings (NASDAQ: OSRH) has provided a detailed update on its equity financing instruments, particularly focusing on its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund. The company has issued 2,308,382 total shares under structured financing, including 519,481 commitment shares, 745,193 convertible notes, and 276,208 warrant exercises.

Under the ELOC agreement, which has a registered share capacity of 9,500,000, only 767,500 shares have been issued since June 17, 2025, representing less than 10% utilization. The company emphasized that proceeds are being invested in their drug R&D pipeline, medical device initiatives, and digital asset ecosystems.

Additionally, OSRH revealed that Woori IO's clinical trial in Korea is being conducted in partnership with a major technology company in mobile and wearable devices, with the Stock Purchase Agreement expected to complete by October.

OSR Holdings (NASDAQ: OSRH) has provided a strategic update on its Term Sheet with Woori IO (WORIO), a South Korean medical device company developing noninvasive glucose monitoring technology. The transaction will make WORIO a wholly-owned subsidiary of OSRH's Korean affiliate, OSRK.

Under the agreement, WORIO shareholders will receive OSRK shares with a conditional right to exchange them for OSRH common stock if OSRH's share price reaches $10.00 within three years, representing a nearly 10x premium over current trading levels. The global blood glucose monitoring device market is projected to reach $40 billion by 2030.

WORIO's technology uses near-infrared spectroscopy for needle-free glucose measurement, suitable for smartwatch integration. The company has completed a proof-of-concept study and is preparing for a larger confirmatory study for Korean regulatory approval.

OSR Holdings (NASDAQ: OSRH) has signed a term sheet to acquire Woori IO (WORIO), a South Korean company developing noninvasive glucose monitoring technology. The acquisition will be executed through OSR's Korean affiliate, OSRK, with WORIO becoming its wholly-owned subsidiary.

The deal structure allows WORIO shareholders to receive OSRK shares, potentially convertible to OSRH shares at a 1:12.96 ratio if OSRH's stock reaches $10.00 within three years. WORIO's technology uses near-infrared spectroscopy for needle-free glucose monitoring, targeting the $40 billion blood glucose monitoring market expected by 2030.

WORIO has completed a proof-of-concept study with Korea University Hospital and was selected for Samsung Electronics' C-Lab Outside program in Q1 2025. The agreement includes a 6-month exclusivity period for due diligence completion.

OSR Holdings (NASDAQ: OSRH) has appointed Dr. Andreas Niethammer as Chief Medical Officer of its subsidiary Vaximm AG. Dr. Niethammer, who co-founded Vaximm, is returning to lead the clinical development of the company's oral T-cell activator platform, including the clinical-stage candidate VXM01.

With over 20 years of experience in cancer immunotherapy, Dr. Niethammer brings significant expertise from leadership roles at companies like Fate Therapeutics, NantKwest, and Pfizer. He originally developed the concept of oral T-cell vaccination at the Scripps Research Institute and has successfully advanced VXM01 into clinical trials for pancreatic cancer and glioblastoma.

OSR Holdings (NASDAQ:OSRH) has unveiled plans for a $50 million security token offering (STO) under Regulation D in H2 2025. The company will launch OSRT, a security token representing OSRH equity exposure, accepting Bitcoin (BTC), Tether (USDT), and Taekwondo Access Credit (TAC) as subscription currencies.

The initiative is part of OSRH's broader strategy to build a $100 million Bitcoin and USDT reserve, supported by an $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund. BCM Europe AG, OSRH's largest shareholder, will convert its TAC holdings to BTC/USDT before participating in the offering to ensure compliance and avoid insider trading concerns.